196302-51-9

Upstream product

• 68216-65-9 3-bromo-2,5-dimethoxybenzaldehyde 
• 100940-12-3 2,5-dimethoxy-3-bromobenzoic acid 
• 672-13-9 2-hydroxy-5-methoxybenzaldehyde 
• 50343-02-7 3-Bromo-2-hydroxy-5-methoxy-benzaldehyde 

Downstream Products

• 196302-52-0 1-Bromo-3-chloromethyl-2,5-dimethoxy-benzene 
• 669065-53-6 [1(1RS,3Z,5R,6S,7S),3R]-N-{3-[1-benzenesulfonyl-7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-butyramide 
• 669065-54-7 [1(3Z,5R,6S,7S),3R]-N-{3-[7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-44-5 [1(3Z,5R,6S,7S),3R]-N-{3-[7,9-bis(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-(tert-butyldimethylsilyloxy)-3-methoxy-butyramide 
• 669065-55-8 [1(3Z,5R,6S,7S),3R]-N-{3-[7-(tert-butyl-dimethylsilyloxy)-9-hydroxy-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-4-hydroxy-3-methoxy-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-45-6 [1(3Z,5R,6S,7S),3R]-N-{3-[7-(tert-butyl-dimethylsilyloxy)-9-oxo-4,6-dimethyl-5-triisopropylsilyloxy-non-3-enyl]-2,5-dimethoxy-phenyl}-3-methoxy-4-oxo-N-(2,2,2-trichloroethoxymethyl)-butyramide 
• 669065-35-4 [1(3Z,5R,6S,7S,9E),3R,4E]-3-methoxy-hepta-4,6-dienoic acid {3-[7-(tert-butyl-dimethylsilyloxy)-4,6-dimethyl-5-triisopropylsilyloxy-dodeca-3,9,11-trienyl]-2,5-dimethoxy-phenyl}-amide 
• 669065-37-6 1-bromo-3-benzenesulfonylmethyl-2,5-dimethoxymethylbenzene 
• 198757-93-6 (R)-N-(3-benzenesulfonylmethyl-2,5-dimethoxyphenyl)-4-(tert-butyldimethylsilyloxy)-3-methoxybutyramide 
• 551001-22-0 5-Hydroxy-2-(4-hydroxy-phenyl)-7-methoxy-benzofuran-4-carbaldehyde 
• 782486-32-2 7-bromo-2-(3-fluoro-4-hydroxy-phenyl)-benzofuran-5-ol 
• 551001-66-2 2-(3-Bromo-2,5-dimethoxy-phenyl)-1-(4-methoxy-phenyl)-ethanone 
• 551001-68-4 7-bromo-2-(4-hydroxy-phenyl)-benzofuran-5-ol 
• 551001-19-5 2-(4-Hydroxy-phenyl)-7-methoxy-benzofuran-5-ol 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION

The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

Palladium-mediated synthesis of calothrixin B

An efficient synthesis of the indolo[3,2-j]phenanthridine alkaloid calothrixin B is described. The relative ease and high yields of this synthesis make this an attractive route for the preparation of calothrixin B derivatives for structure-activity relati

Tetracyclic compounds as estrogen ligands

This invention provides estrogen receptor modulators having the structure: wherein R1, R2, R3, R4, Q, n, R8, R9, R10, and R11 have been defined in the specification; o

A Convergent Synthesis of the Macrocyclic Core of Cytotrienins: Application of RCM for Macrocyclization

(Equation presented) The asymmetric synthesis of the fully elaborated macrocyclic core of cytotrienins A-D, potent apoptosis-inducing agents, is described. Synthetic highlights include the construction of the aniline bond using a copper-mediated amidation and the use of a ring-closing metathesis (RCM) reaction to efficiently install the (E,E,E)-triene and simultaneously construct the macrocyclic lactam.

Substituted 2-phenyl benzofurans as estrogenic agents

This invention provides estrogen receptor modulators of formula I, having the structure wherein R, R′, A, A′, X, Y, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.

AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF

The invention relates to aminotetralin derivatives of the formula I: wherein: R1 is methyl or ethyl; R2 is hydrogen, halogen, lower-alkoxy or thiolower-alkyl; R3 is hydrogen, halogen, lower-alkoxy or lower-alkyl; and the chiral center * is in the

Aminotetralin derivative and compositions and method of use thereof

The invention relates to aminotetralin derivatives of the formula I: STR1 wherein: R1 is methyl or ethyl; R2 is hydrogen, halogen, lower-alkoxy or thiolower-alkyl; R3 is hydrogen, halogen, lower-alkoxy or lower-alkyl; and